Pharmacogenomics and breast cancer

Pharmacogenomics

Volumn 5, Issue 1, 2004, Pages 31-55

  Lymberis, Stella C ^a   Parhar, Preeti K ^a   Katsoulakis, Evangelista ^a   Formenti, Silvia C ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Chemotherapy; Germline; Pharmacogenomics; Polymorphism; Radiation therapy; SNP; Variants

Indexed keywords

ACYLTRANSFERASE; ANDROGEN RECEPTOR; ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CARCINOGEN; CYTOCHROME P450C17; DRUG METABOLIZING ENZYME; ESTROGEN; FLUOROURACIL; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN; HEAT SHOCK PROTEIN 70; INTEGRIN; ONCOPROTEIN; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; STROMELYSIN; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA;

BREAST CANCER; BREAST FIBROSIS; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; CELL ADHESION; DNA REPAIR; DRUG EFFICACY; DRUG ERUPTION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG RESPONSE; DRUG TARGETING; DRUG TRANSPORT; ESTROGEN METABOLISM; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GERM LINE; HEREDITY; HUMAN; PHARMACOGENOMICS; REVIEW; SKIN ULCER;

ANIMALS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASM PROTEINS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 0347766085     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/phgs.5.1.31.25686     Document Type: Review

References (223)

1. Sachidanandam R, Weissman D, Schmidt SC et al.: A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409(6822), 928-933 (2001).
2. Balmain A, Gray J, Ponder B: The genetics and genomics of cancer. Nat. Genet. 33 Suppl., 238-244 (2003).
3. Ford D, Easton DF, Stratton M et al.: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer linkage Consortium. Am. J. Hum. Genet. 62(3), 676-689 (1998).
4. Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF: A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 8(10), 843-854 (1999).
5. de Jong MM, Nolte IM, te Meerman GJ et al.: Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J. Med. Genet. 39(4), 225-242 (2002).
6. Thorlacius S, Struewing JP, Hartge P et al.: Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 352(9137), 1337-1339 (1998).
7. Struewing JP, Hartge P, Wacholder S et al.: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med. 336(20), 1401-1408 (1997).
8. Rebbeck TR, Godwin AK, Buetow KH: Variability in loss of constitutional heterozygosity across loci and among individuals: association with candidate genes in ductal breast carcinoma. Mol. Carcinog. 17(3), 117-125 (1996).
9. King MC, Marks JH, Mandell JB: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645), 643-646 (2003).
10. Fuks F, Milner J, Kouzarides T: BRCA2 associates with acetyltransferase activity when bound to P/CAF. Oncogene 17(19), 2531-2534 (1998).
11. Healey CS, Dunning AM, Teare MD et al.: A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat. Genet. 26(3), 362-364 (2000).
12. Spurdle AB, Hopper JL, Chen X et al.: The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 years. Cancer Epidemiol. Biomarkers Prev. 11(4), 413-416 (2002).
13. Ishitobi M, Miyoshi Y, Ando A et al.: Association of BRCA2 polymorphism at codon 784 (Met/Val) with breast cancer risk and prognosis. Clin. Cancer Res. 9(4), 1376-1380 (2003).
14. Varley JM, McGown G, Thorncroft M et al.: Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res. 57(15), 3245-3252 (1997).
15. Balint EE, Vousden KH: Activation and activities of the p53 tumour suppressor protein. Br. J. Cancer 85(12), 1813-1823 (2001).
16. Sjalander A, Birgander R, Kivela A, Beckman G: p53 polymorphisms and haplotypes in different ethnic groups. Hum. Hered. 45(3), 144-149 (1995).
17. Campbell IG, Eccles DM, Dunn B, Davis M, Leake V: p53 polymorphism in ovarian and breast cancer. Lancet 347(8998), 393-394 (1996).
18. Sjalander A, Birgander R, Hallmans G et al.: p53 Polymorphisms and haplotypes in breast cancer. Carcinogenesis 17(6), 1313-1316 (1996).
19. Weston A, Pan CF, Ksieski HB et al.: p53 Haplotype determination in breast cancer. Cancer Epidemiol. Biomarkers Prev. 6(2), 105-112 (1997).
20. Wang-Gohrke S, Rebbeck TR, Besenfelder W, Kreienberg R, Runnebaum IB: p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anti-Cancer Res. 18(3B), 2095-2099 (1998).
21. Khaliq S, Hameed A, Khaliq T et al.: P53 mutations, polymorphisms, and haplotypes in Pakistani ethnic groups and breast cancer patients. Genet. Test 4(1), 23-29 (2000).
22. Wang-Gohrke S, Becher H, Kreienberg R, Runnebaum IB, Chang-Claude J: Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. Pharmacogenetics 12(3), 269-272 (2002).
23. Peller S, Kopilova Y, Slutzki S, Halevy A, Kvitko K, Rotter V: A novel polymorphism in intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility. DNA Cell Biol. 14(12), 983-990 (1995).
24. Mavridou D, Gornall R, Campbell IG, Eccles DM: TP53 intron 6 polymorphism and the risk of ovarian and breast cancer. Br. J. Cancer 77(4), 676-677 (1998).
25. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S: Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 14(6), 1085-1089 (1993).
26. Liaw D, Marsh DJ, Li J et al.: Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 16(1), 64-67 (1997).
27. Nelen MR, Padberg GW, Peeters EA et al.: Localization of the gene for Cowden disease to chromosome 10q22-23. Nat. Genet. 13(1), 114-116 (1996).
28. Marsh DJ, Coulon V, Lunetta KL et al.: Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum. Mol. Genet. 7(3), 507-515 (1998).
29. Carroll BT, Couch FJ, Rebbeck TR, Weber BL: Polymorphisms in PTEN in breast cancer families. J. Med. Genet. 36(2), 94-96 (1999).
30. Gatti RA, Boder E, Vinters HV, Sparkes RS, Norman A, Lange K: Ataxia-telangiectasia: an interdisciplinary approach to pathogenesis. Medicine (Baltimore) 70(2), 99-117 (1991).
31. Shiloh Y: Ataxia-telangiectasia: closer to unraveling the mystery. Eur. J. Hum. Genet. 3(2), 116-138 (1995).
32. Shiloh Y, Rotman G: Ataxia-telangiectasia and the ATM gene: linking neurodegeneration, immunodeficiency, and cancer to cell cycle checkpoints. J. Clin. Immunol. 16(5), 254-260 (1996).
33. Savitsky K, Bar-Shira A, Gilad S et al.: A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268(5218), 1749-1753 (1995).
34. Lavin MF, Shiloh Y: The genetic defect in ataxia-telangiectasia. Ann. Rev. Immunol. 15, 177-202 (1997).
35. Gilad S, Chessa L, Khosravi R et al.: Genotype-phenotype relationships in ataxia-telangiectasia and variants. Am. J. Hum. Genet. 62(3), 551-561 (1998).
36. Sandoval N, Platzer M, Rosenthal A et al.: Characterization of ATM gene mutations in 66 ataxia telangiectasia families. Hum. Mol. Genet. 8(1), 69-79 (1999).
37. Teraoka SN, Telatar M, Becker-Catania S et al.: Splicing defects in the ataxia-telangiectasia gene, ATM: underlying mutations and consequences. Am. J. Hum. Genet. 64(6), 1617-1631 (1999).
38. Shigeta T, Takagi M, Delia D et al.: Defective control of apoptosis and mitotic spindle checkpoint in heterozygous carriers of ATM mutations. Cancer Res. 59(11), 2602-2607 (1999).
39. Swift M, Reitnauer PJ, Morrell D, Chase CL: Breast and other cancers in families with ataxia-telangiectasia. N. Engl. J. Med. 316(21), 1289-1294 (1987).
40. Easton DF: Cancer risks in A-T heterozygotes. Int. J. Radiat. Biol. 66(6, Suppl.), S177-S182 (1994).
41. Inskip HM, Kinlen LJ, Taylor AM, Woods CG, Arlett CF: Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia. Br. J. Cancer 79(7-8), 1304-1307 (1999).
42. Janin N, Andrieu N, Ossian K et al.: Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families. Br. J. Cancer 80(7), 1042-1045 (1999).
43. Athma P, Rappaport R, Swift M: Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet. Cytogenet. 92(2), 130-134 (1996).
44. Angele S, Hall J: The ATM gene and breast cancer: is it really a risk factor? Mutat. Res. 462(2-3), 167-178 (2000).
45. Fitzgerald MG, Bean JM, Hegde SR et al.: Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat. Genet. 15(3), 307-310 (1997).
46. Chen J, Birkholtz GG, Lindblom P, Rubio C, Lindblom A. The role of ataxia-telangiectasia heterozygotes in familial breast cancer. Cancer Res. 58(7), 1376-1379 (1998).
47. Bretsky P, Haiman CA, Gilad S et al.: The relationship between twenty missense ATM variants and breast cancer risk: the Multiethnic Cohort. Cancer Epidemiol. Biomarkers Prev. 12(8), 733-738 (2003).
48. Nathanson KL, Weber BL: 'Other' breast cancer susceptibility genes: searching for more holy grail. Hum. Mol. Genet. 10(7), 715-720 (2001).
49. Wooster R, Weber BL: Breast and ovarian cancer. N. Engl. J. Med. 348(23), 2339-2347 (2003).
50. Lichtenstein P, Holm NV, Verkasalo PK et al.: Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 343(2), 78-85 (2000).
51. Krontiris TG, DiMartino NA, Colb M, Parkinson DR: Unique allelic restriction fragments of the human H-ras locus in leukocyte and tumour DNAs of cancer patients. Nature 313(6001), 369-374 (1985).
52. Krontiris TG, Devlin B, Karp DD, Robert NJ, Risch N: An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. N. Engl. J. Med. 329(8), 517-523 (1993).
53. Garrett PA, Hulka BS, Kim YL, Farber RA: HRAS protooncogene polymorphism and breast cancer. Cancer Epidemiol. Biomarkers Prev. 2(2), 131-138 (1993).
54. Firgaira FA, Seshadri R, McEvoy CR et al.: HRAS1 rare minisatellite alleles and breast cancer in Australian women under age forty years. J. Natl. Cancer Inst. 91(24), 2107-2111 (1999).
55. Hopper JL, Firgaira FA, Dite GS et al.: RESPONSE: re: HRAS1 rare minisatellite alleles and breast cancer in Australian women under age forty years. J. Nat. Cancer Inst. 92(9), 756-757 (2000).
56. Krontiris TG: RESPONSE: Re: HRAS1 rare minisatellite alleles and breast cancer in Australian women under age forty years. J. Natl. Cancer Inst. 92(9), 755-757 (2000).
57. Lee JS, Collins K, Brown A, Lee CH, Chung JH: The function of BRCA1 in DNA damage response. Cold Spring Harb. Symp. Quant. Biol. 65, 547-552 (2000).
58. Chehab NH, Malikzay A, Appel M, Halazonetis TD: Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev. 14(3), 278-288 (2000).
59. Shich SY, Ahn J, Tamai K, Taya Y, Prives C: The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 14(3), 289-300 (2000).
60. Meijers-Heijboer H, van den Ouweland A, Klijn J et al.: Low-penetrance susceptibility to breast cancer due to CHEK2(* 1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat. Genet. 31(1), 55-59 (2002).
61. Vahteristo P, Bartkova J, Eerola H et al.: A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am. J. Hum. Genet. 71(2), 432-438 (2002).
62. Schutte M, Seal S, Barfoot R et al.: Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Am. J. Hum. Genet. 72(4), 1023-1028 (2003).
63. Kuschel B, Auranen A, Gregory CS et al.: Common polymorphisms in checkpoint kinase 2 are not associated with breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 12(8), 809-812 (2003).
64. Meijers-Heijboer H, Wijnen J, Vasen H et al.: The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am. J. Hum. Genet. 72(5), 1308-1314 (2003).
65. Offit K, Pierce H, Kirchhoff T et al.: Frequency of CHEK2*1100delC in New York breast cancer cases and controls. BMC Med. Genet. 4(1), 1 (2003).
66. Yu Z, Chen J, Ford BN, Brackley ME, Glickman BW: Human DNA repair systems: an overview. Environ. Mol. Mutagen. 33(1), 3-20 (1999).
67. Shen MR, Jones IM, Mohrenweiser H: Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res. 58(4), 604-608 (1998).
68. Duell EJ, Millikan RC, Pittman GS et al.: Polymorphisms in the DNA repair gene XRCC1 and breast cancer. Cancer Epidemiol. Biomarkers Prev. 10(3), 217-222 (2001).
69. Kim SU, Park SK, Yoo KY et al.: XRCC1 genetic polymorphism and breast cancer risk. Pharmacogenetics 12(4), 335-338 (2002).
70. Johnson RD, Liu N, Jasin M: Mammalian XRCC2 promotes the repair of DNA double-strand breaks by homologous recombination. Nature 401(6751), 397-399 (1999).
71. Brenneman MA, Weiss AE, Nickoloff JA, Chen DJ: XRCC3 is required for efficient repair of chromosome breaks by homologous recombination. Mutat. Res. 459(2), 89-97 (2000).
72. Rafii S, O'Regan P, Xinarianos G et al.: A potential role for the XRCC2 R188H polymorphic site in DNA-damage repair and breast cancer. Hum. Mol. Genet. 11(12), 1433-1438 (2002).
73. Chen JJ, Silver D, Cantor S, Livingston DM, Scully R: BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res. 59(7, Suppl.), 1752s-1756s (1999).
74. Wang WW, Spurdle AB, Kolachana P et al.: A single nucleotide polymorphism in the 5′ untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol. Biomarkers Prev. 10(9), 955-960 (2001).
75. Levy-Lahad E, Lahad A, Eisenberg S et al.: A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc. Natl. Acad. Sci. USA 98(6), 3232-3236 (2001).
76. Jakubowska A, Narod SA, Goldgar DE et al.: Breast cancer risk reduction associated with the RAD51 polymorphism among carriers of the BRCA1 5382insC mutation in Poland. Cancer Epidemiol. Biomarkers Prev. 12(5), 457-459 (2003).
77. Cui X, Brenneman M, Meyne J, Oshimura M, Goodwin EH, Chen DJ: The XRCC2 and XRCC3 repair genes are required for chromosome stability in mammalian cells. Mutat. Res. 434(2), 75-88 (1999).
78. Matullo G, Palli D, Peluso M et al.: XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 22(9), 1437-1445 (2001).
79. Matullo G, Peluso M, Polidoro S et al.: Combination of DNA repair gene single nucleotide polymorphisms and increased levels of DNA adducts in a population-based study. Cancer Epidemiol. Biomarkers Prev. 12(7), 674-677 (2003).
80. Smith TR, Miller MS, Lohman K et al.: Polymorphisms of XRCC1 and XRCC3 genes and susceptibility to breast cancer. Cancer Lett. 190(2), 183-190 (2003).
81. Kuschel B, Auranen A, McBride S et al.: Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum. Mol. Genet. 11(12), 1399-1407 (2002).
82. Badawi AF, Hirvonen A, Bell DA, Lang NP, Kadlubar FF: Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res. 55(22), 5230-5237 (1995).
83. Hein DW, Doll MA, Rustan TD et al.: Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 14(8), 1633-1638 (1993).
84. Rebbeck TR: Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol. Biomarkers Prev. 6(9), 733-743 (1997).
85. Van der Hel OL, Peeters PH, Hein DW et al.: NAT2 slow acetylation and GSTM1 null genotypes may increase postmenopausal breast cancer risk in long-term smoking women. Pharmacogenetics 13(7), 399-407 (2003).
86. Lee KM, Park SK, Kim SU, Doll MA et al.: N-Acetyltransferase (NAT1, NAT2) and glutathione S-transferase (GSTM1, GSTT1) polymorphisms in breast cancer. Cancer Lett. 196(2), 179-186 (2003).
87. Ambrosone CB, Freudenheim JL, Thompson PA et al.: Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer. Cancer Res. 59(3), 602-606 (1999).
88. Mitrunen K, Sillanpaa P, Kataja V et al.: Association between manganese superoxide dismutase (MnSOD) gene polymorphism and breast cancer risk. Carcinogenesis 22(5), 827-829 (2001).
89. Begg L, Kuller LH, Gutai JP, Caggiula AG, Wolmark N, Watson CG: Endogenous sex hormone levels and breast cancer risk. Genet. Epidemiol. 4(4), 233-247 (1987).
90. Hulka BS: Epidemiologic analysis of breast and gynecologic cancers. Prog. Clin. Biol. Res. 396, 17-29 (1997).
91. Mitrunen K, Hirvonen A: Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. Mutat. Res. 544(1), 9-41 (2003).
92. De Vivo I, Hankinson SE, Li L, Colditz GA, Hunter DJ: Association of CYP1B1 polymorphisms and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 11(5), 489-492 (2002).
93. Bailey LR, Roodi N, Dupont WD, Parl FF: Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res. 58(22), 5038-5041 (1998).
94. Stoilov I, Akarsu AN, Alozie I et al.: Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am. J. Hum. Genet. 62(3), 573-584 (1998).
95. Rylander-Rudqvist T, Wedren S, Granath F et al.: Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk. Carcinogenesis 24(9), 1533-1539 (2003).
96. Watanabe J, Shimada T, Gillam EM et al.: Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics (2000) 10(1), 25-33 (2000).
97. Weber BL, Nathanson KL: Low penetrance genes associated with increased risk for breast cancer. Eur. J. Cancer 36(10), 1193-1199 (2000).
98. Fontana X, Peyrottes I, Rossi C et al.: Study of the frequencies of CYP1A1 gene polymorphisms and glutathione S-transferase mu1 gene in primary breast cancers: an update with an additional 114 cases. Mutat. Res. 403(1-2), 45-53 (1998).
99. Ishibe N, Hankinson SE, Colditz GA et al.: Cigarette smoking, cytochrome P450 1A1 polymorphisms, and breast cancer risk in the Nurses' Health Study. Cancer Res. 58(4), 667-671 (1998).
100. Taioli E, Bradlow HL, Garbers SV et al.: Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk. Cancer Detect. Prev. 23(3), 232-237 (1999).
101. Bailey LR, Roodi N, Verrier CS, Yee CJ, Dupont WD, Parl FF: Breast cancer and CYPIA1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. Cancer Res. 58(1), 65-70 (1998).
102. Huang CS, Shen CY, Chang KJ, Hsu SM, Chern HD: Cytochrome P4501A1 polymorphism as a susceptibility factor for breast cancer in postmenopausal Chinese women in Taiwan. Br. J. Cancer 80(11), 1838-1843 (1999).
103. Ambrosone CB, Freudenheim JL, Graham S et al.: Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res, 55(16), 3483-3485 (1995).
104. Thompson PA, Shields PG, Freudenheim JL et al.: Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk. Cancer Res. 58(10), 2107-2110 (1998).
105. Yun DS, Parkb SK, Yoo KY et al.: Relationship between the Val158Met polymorphism of catechol O-methyl transferase and breast cancer. Pharmacogenetics 11(4), 279-286 (2001).
106. Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY: Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res. 59(19), 4870-4875 (1999).
107. Brentano ST, Picado-Leonard J, Mellon SH, Moore CC, Miller WL: Tissue-specific, cyclic adenosine 3′,5′-monophosphate-induced, and phorbol ester-repressed transcription from the human P450c17 promoter in mouse cells. Mol. Endocrinol. 4(12), 1972-1979 (1990).
108. Feigelson HS, McKean-Cowdin R, Pike MC et al.: Cytochrome P450c17alpha gene (CYP17) polymorphism predicts use of hormone replacement therapy. Cancer Res. 59(16), 3908-3910 (1999).
109. Ye Z, Parry JM: The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis 17(2), 119-126 (2002).
110. Feigelson HS, McKean-Cowdin R, Henderson BE: Concerning the CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis 17(5), 445-446; author reply 447-448 (2002).
111. Ambrosone CB, Moysich KB, Furberg H et al.: CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors. Breast Cancer Res. 5(2), R45-R51 (2003).
112. Kristensen VN, Andersen TI, Lindblom A, Erikstein B, Magnus P, Borresen-Dale AL: A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics 8(1), 43-48 (1998).
113. Probst-Hensch NM, Ingles SA, Diep AT et al.: Aromatase and breast cancer susceptibility. Endocr. Relat. Cancer 6(2), 165-173 (1999).
114. Siegelmann-Danieli N, Buetow KH: Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br. J. Cancer 79(3-4), 456-463 (1999).
115. Haiman CA, Hankinson SE, Spiegelman D et al.: A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int. J. Cancer 87(2), 204-210 (2000).
116. Healey CS, Dunning AM, Durocher F et al.: Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Carcinogenesis 21(2), 189-193 (2000).
117. Kristensen VN, Harada N, Yoshimura N et al.: Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene 19(10), 1329-1333 (2000).
118. Rubin GL, Zhao Y, Kalus AM, Simpson ER: Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res. 60(6), 1604-1608 (2000).
119. Bulun SE, Price TM, Aitken J, Mahendroo MS, Simpson ER: A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J. Clin. Endocrinol. Metab. 77(6), 1622-1628 (1993).
120. Simpson ER, Zhao Y, Agarwal VR et al.: Aromatase expression in health and disease. Recent Prog. Horm. Res. 52, 185-213; discussion 213-214 (1997).
121. Memisoglu A, Hankinson SE, Manson JE, Colditz GA, Hunter DJ: Lack of association of the colon 12 polymorphism of the peroxisome proliferator-activated receptor gamma gene with breast cancer and body mass. Pharmacogenetics 12(8), 597-603 (2002).
122. Andersen TI, Heimdal KR, Skrede M, Tveit K, Berg K, Borresen AL: Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility. Hum. Genet. 94(6), 665-670 (1994).
123. Roodi N, Bailey LR, Kao WY et al.: Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J. Natl. Cancer Inst. 87(6), 446-451 (1995).
124. Hill SM, Fuqua SA, Chamness GC, Greene GL, McGuire WL: Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism. Cancer Res. 49(1), 145-148 (1989).
125. Iwase H, Greenman JM, Barnes DM, Hodgson S, Bobrow L, Mathew CG: Sequence variants of the estrogen receptor (ER) gene found in breast cancer patients with ER negative and progesterone receptor positive tumors. Cancer Lett. 108(2), 179-184 (1996).
126. Southey MC, Batten LE, McCredie MR et al.: Estrogen receptor polymorphism at codon 325 and risk of breast cancer in women before age forty. J. Natl. Cancer Inst. 90(7), 532-536 (1998).
127. Wang-Gohrke S, Chang-Claude J, Becher H, Kieback DG, Runnebaum IB: Progesterone receptor gene polymorphism is associated with decreased risk for breast cancer by age 50. Cancer Res. 60(9), 2348-2350 (2000).
128. Rowe SM, Coughlan SJ, McKenna NJ et al.: Ovarian carcinoma-associated TaqI restriction fragment length polymorphism in intron G of the progesterone receptor gene is due to an Alu sequence insertion. Cancer Res. 55(13), 2743-2745 (1995).
129. Manolitsas TP, Englefield P, Eccles DM, Campbell IG: No association of a 306-bp insertion polymorphism in the progesterone receptor gene with ovarian and breast cancer. Br. J. Cancer 75(9). 1398-1399 (1997).
130. Lancaster JM, Berchuck A, Carney ME, Wiseman R, Taylor JA: Progesterone receptor gene polymorphism and risk for breast and ovarian cancer. Br. J. Cancer 78(2), 277 (1998).
131. De Vivo I, Hankinson SE, Colditz GA, Hunter DJ: A functional polymorphism in the progesterone receptor gene is associated with an increase in breast cancer risk. Cancer Res. 63(17), 5236-5238 (2003).
132. Dorgan JF, Longcope C, Stephenson HE Jr et al.: Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 5(7), 533-539 (1996).
133. Berrino F, Muti P, Micheh A et al.: Serum sex hormone levels after menopause and subsequent breast cancer. J. Natl. Cancer Inst. 88(5), 291-296 (1996).
134. Thomas HV, Key TJ, Allen DS et al.: A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Br. J. Cancer 76(3), 401-405 (1997).
135. Zeleniuch-Jacquotte A, Bruning PF, Bonfrer JM et al.: Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women. Am. J. Epidemiol. 145(11), 1030-1038 (1997).
136. Hankinson SE, Willett WC, Manson JE et al.: Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J. Natl. Cancer Inst. 90(17), 1292-1299 (1998).
137. Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR: Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann. Intern. Med. 130(4, Pt 1), 270-277 (1999).
138. Wysowski DK, Comstock GW, Helsing KJ, Lau HL: Sex hormone levels in serum in relation to the development of breast cancer. Am. J. Epidemiol. 125(5), 791-799 (1987).
139. Garland CF, Friedlander NJ, Barrett-Connor E, Khaw KT: Sex hormones and postmenopausal breast cancer: a prospective study in an adult community. Am. J. Epidemiol. 135(11), 1220-1230 (1992).
140. Endogenous Hormones and Breast Cancer Collaborative Group: Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J. Natl. Cancer Inst. 94(8), 606-616 (2002).
141. Lillie EO, Bernstein L, Ursin G: The role of androgens and polymorphisms in the androgen receptor in the epidemiology of breast cancer. Breast Cancer Res. 5(3), 164-173 (2003).
142. Wooster R, Mangion J, Eeles R et al.: A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nat. Genet. 2(2), 132-134 (1992).
143. Lubahn DB, Brown TR, Simental JA et al.: Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity. Proc. Natl. Acad. Sci. USA 86(23), 9534-9538 (1989).
144. Irvine RA, Ma H, Yu MC, Ross RK, Stallcup MR, Coetzee GA: Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Hum. Mol. Genet. 9(2), 267-274 (2000).
145. Haiman CA, Brown M, Hankinson SE et al.: The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses' Health Study. Cancer Res. 62(4), 1045-1049 (2002).
146. Westberg L, Baghaei F, Rosmond R et al.: Polymorphisms of the androgen receptor gene and the estrogen receptor beta gene are associated with androgen levels in women. J. Clin. Endocrinol. Metab. 86(6), 2562-2568 (2001).
147. Ayala F, Corral J, Gonzalez-Conejero R, Sanchez I, Moraleda JM, Vicente V: Genetic polymorphisms of platelet adhesive molecules: association with breast cancer risk and clinical presentation. Breast Cancer Res. Treat. 80(2), 145-154 (2003).
148. Tucker GC: Inhibitors of integrins. Curr. Opin. Pharmacol. 2(4), 394-402 (2002).
149. Hood JD, Cheresh DA: Role of integrins in cell invasion and migration. Nat. Rev. Cancer 2(2), 91-100 (2002).
150. Felding-Habermann B, O'Toole TE, Smith JW et al.: Integrin activation controls metastasis in human breast cancer. Proc. Natl. Acad. Sci. USA 98(4), 1853-1858 (2001).
151. Bojesen SE, A Tybjaerg-Hansen, Nordestgaard BG: Integrin beta.3 Leu33Pro homozygosity and risk of cancer. J. Natl. Cancer Inst. 95(15), 1150-1157 (2003).
152. Sternlicht MD, Bissell MJ, Werb Z: The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene 19(8), 1102-1113 (2000).
153. Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM: Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br. Heart J. 73(3), 209-215 (1995).
154. Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM: Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J. Biol. Chem. 271(22), 13055-13060 (1996).
155. Ghilardi G, Biondi ML, Caputo M et al.: A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin. Cancer Res. 8 (12), 3820-3823 (2002).
156. Reiss M, Barcellos-Hoff MH: Transforming growth factor-beta in breast cancer: a working hypothesis. Breast Cancer Res. Treat. 45(1), 81-95 (1997).
157. Dunning AM, Ellis PD, McBride S et al.: A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res. 63(10), 2610-2615 (2003).
158. Yokota M, Ichihara S, Lin TL, Nakashima N, Yamada Y: Association of a T29→C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 101(24), 2783-2787 (2000).
159. Hishida A, Iwata H, Hamajima N et al.: Transforming growth factor B1 T29C polymorphism and breast cancer risk in Japanese women. Breast Cancer 10(1), 63-69 (2003).
160. Ziv E, Cauley J, Morin PA, Saiz R, Browner WS: Association between the T29→ C polymorphism in the transforming growth factor beta1 gene and breast cancer among elderly white women: the study of osteoporotic fractures. JAMA 285(22), 2859-2863 (2001).
161. Pasche B, Kolachana P, Nafa K et al.: TbetaR-I(6A) is a candidate tumor susceptibility allele. Cancer Res. 59(22), 5678-5682 (1999).
162. Grainger DJ, Heathcote K, Chiano M et al.: Genetic control of the circulating concentration of transforming growth factor type beta1. Hum. Mol. Genet. 8(1), 93-97 (1999).
163. Milner CM, Campbell RD: Polymorphic analysis of the three MHC-linked HSP70 genes. Immunogenetics 36(6), 357-362 (1992).
164. Suto R, Srivastava PK: A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 269(5230), 1585-1588 (1995).
165. Chouchane L, Ahmed SB, Baccouche S, Remadi S: Polymorphism in the tumor necrosis factor-alpha promotor region and in the heat shock protein 70 genes associated with malignant rumors. Cancer 80(8), 1489-1496 (1997).
166. Mestiri S, Bouaouina N, Ahmed SB et al.: Genetic variation in the tumor necrosis factor-alpha promoter region and in the stress protein hsp70-2: susceptibility and prognostic implications in breast carcinoma. Cancer 91(4), 672-678 (2001).
167. Evans WE, McLeod HL: Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med. 348(6), 538-549 (2003).
168. Watters JW, McLeod HL: Cancer pharmacogenomics: current and future applications. Biochim. Biophys. Acta 1603(2), 99-111 (2003).
169. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J. Clin. Oncol. 16(11), 3537-3541 (1998).
170. Lu Z, Zhang R, Diasio RB: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res. 53(22), 5433-5438 (1993).
171. Van Kuilenburg AB, Haasjes J, Richel DJ et al.: Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin. Cancer Res. 6(12), 4705-4712 (2000).
172. Van Kuilenburg AB, Muller EW, Haasjes J et al.: Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin. Cancer Res. 7(5), 1149-1153 (2001).
173. Van Kuilenburg AB, Meinsma R, Zonnenberg BA et al.: Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin. Cancer Res. 9(12), 4363-4367 (2003).
174. Raida M, Schwabe W, Hausler P et al.: Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin.
175. Johnson MR, Diasio RB: Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv. Enzyme Regul. 41, 151-157 (2001).
176. Collie-Duguid ES, Etienne MC, Milano G, McLeod HL: Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 10(3), 217-223 (2000).
177. Duran M, Rovers P, de Bree PK et al.: Dihydropyrimidinuria: a new inborn error of pyrimidine metabolism. J. Inherit. Metab. Dis. 14(3), 367-370 (1991).
178. Hayashi K, Kidouchi K, Sumi S et al.: Possible prediction of adverse reactions to pyrimidine chemotherapy from urinary pyrimidine levels and a case of asymptomatic adult dihydropyrimidinuria. Clin. Cancer Res. 2(12), 1937-1941 (1996).
179. Sumi S, Imaeda M, Kidouchi K et al.: Population and family studies of dihydropyrimidinuria: prevalence, inheritance mode, and risk of fluorouracil toxicity. Am. J. Med. Genet. 78(4), 336-340 (1998).
180. Pullarkat ST, Imaeda. M, Kidouchi K et al.: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 1(1), 65-70 (2001).
181. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K: Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct. Funct. 20(3), 191-197 (1995).
182. Kawakami K, Omura Y, Kanehira E, Watanabe Y: Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res. 19(4B), 3249-3252 (1999).
183. Iacopetta B, Grieu F, Joseph D, Elsaleh H: A polymorphism in the enhancer moon of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br. J. Cancer 85(6), 827-830 (2001).
184. Nagasubramanian R, Innocenti F, Ratain MJ: Pharmacogenetics in cancer treatment. Ann. Rev. Med. 54, 437-452 (2003).
185. Dai D, Zeldin DC, Blaisdell JA et al.: Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11(7), 597-607 (2001).
186. Ambrosone CB, Sweeney C, Coles BF et al.: Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res. 61(19), 7130-7135 (2001).
187. Tew KD: Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 54(16), 4313-4320 (1994).
188. Hayes JD, Strange RC: Potential contribution of the glutathione S-transferase supergene family to resistance to oxidative stress. Free Radic. Res. 22(3), 193-207 (1995).
189. Borger JH, Kemperman H, Smitt HS et al.: Dose and volume effects on fibrosis after breast conservation therapy. Int. J. Radiat. Oncol. Biol. Phys. 30(5), 1073-1081 (1994).
190. Tucker SL, Turesson I, Thames HD: Evidence for individual differences in the radiosensitivity of human skin. Eur. J. Cancer 28A(11), 1783-1791 (1992).
191. Turesson I: Individual variation and dose dependency in the progression rate of skin telangiectasia. Int. J. Radiat. Oncol. Biol. Phys. 19(6), 1569-1574 (1990).
192. Turesson I, Nyman J, Holmberg E, Oden A: Prognostic factors for acute and late skin reactions in radiotherapy patients. Int. J. Radiat. Oncol. Biol. Phys. 36(5), 1065-1075 (1996).
193. Bentzen SM, Overgaard J: Patient-to-patient variability in the expression of radiation-induced normal tissue injury, Semin. Radiat. Oncol. 4(2), 68-80 (1994).
194. Tucker SL, Geara FB, Peters LJ, Brock WA: How much could the radiotherapy dose be altered for individual patients based on a predictive assay of normal-tissue radiosensitivity? Radiother. Oncol. 38(2), 103-113 (1996).
195. Burnet NG, Johansen J, Turesson I, Nyman J, Peacock JH: Describing patients' normal tissue reactions: concerning the possibility of individualising radiotherapy dose prescriptions based on potential predictive assays of normal tissue radiosensitivity. Steering Committee of the BioMed2 European Union Concerted Action Programme on the Development of Predictive Tests of Normal Tissue Response to Radiation Therapy. Int. J. Cancer 79(6), 606-613 (1998).
196. Mackay RI, Hendry JH: The modelled benefits of individualizing radiotherapy patients' dose using cellular radiosensitivity assays with inherent variability. Radiother. Oncol. 50(1), 67-75 (1999).
197. Brock WA, Tucker SL: In vitro radiosensitivity and normal tissue damage. Radiother. Oncol. 55(2), 93-94 (2000).
198. Formenti SC, Chak L, Gill P, Buess EM, Hill CK: Increased radiosensitivity of normal tissue fibroblasts in patients with acquired immunodeficiency syndrome (AIDS) and with Kaposi's sarcoma. Int. J. Radiat. Biol. 68(4), 411-412 (1995).
199. Loeffler JS, Harris JR, Dahlberg WK, Little JB: In vitro radiosensitivity of human diploid fibroblasts derived from women with unusually sensitive clinical responses to definitive radiation therapy for breast cancer. Radiat. Res. 121(2), 227-231 (1990).
200. Deschavaane PJ, Debieu D, Fertil B, Malaise EP: Re-evaluation of in vitro radiosensitivity of human fibroblasts of different genetic origins. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 50(2), 279-293 (1986).
201. Carney JP, Maser RS, Olivares H et al.: The hMre11/hRad5O protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell 93(3), 477-486 (1998).
202. Weissberg JB, Huang DD, Swift M: Radiosensitivity of normal tissues in ataxia-telangiectasia heterozygotes. Int. J. Radiat. Oncol. Biol. Phys. 42(5), 1133-1136 (1998).
203. Clarke RA, Goozee GR, Birrell G et al.: Absence of ATM truncations in patients with severe acute radiation reactions. Int. J. Radiat. Oncol. Biol. Phys. 41(5), 1021-1027 (1998).
204. Ramsay J, Birrell G, Lavin M: Testing for mutations of the ataxia telangiectasia gene in radiosensitive breast cancer patients. Radiother. Oncol. 47(2), 125-128 (1998).
205. Concannon P, Gatti RA: Diversity of ATM gene mutations detected in patients with ataxia-telangiectasia. Hum. Mutat. 10(2), 100-107 (1997).
206. Appleby JM, Barber JB, Levine E et al.: Absence of mutations in the ATM gene in breast cancer patients with severe responses to radiotherapy. Br. J. Cancer 76(12), 1546-1549 (1997).
207. Oppitz U, Bernthaler U, Schindler D et al.: Sequence analysis of the ATM gene in 20 patients with RTOG grade 3 or 4 acute and/or late tissue radiation side effects. Int. J. Radiat. Oncol. Biol. Phys. 44(5), 981-988 (1999).
208. Varghese S, Schmidt-Ullrich RK, Dritschilo A, Jung M: Enhanced radiation late effects and cellular radiation sensitivity in an ATM heterozygous breast cancer patient. Radiat. Oncol. Investig. 7(4), 231-237 (1999).
209. Iannuzzi CM, Atencio DP, Green S, Stock RG, Rosenstein BS: ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Int. J. Radiat. Oncol. Biol. Phys. 52(3), 606-613 (2002).
210. Randall K, Coggle JE: Expression of transforming growth factor-beta 1 in mouse skin during the acute phase of radiation damage. Int. J. Radiat. Biol. 68(3), 301-309 (1995).
211. Barcellos-Hoff MH, Derynck R, Tsang ML, Weatherbee JA: Transforming growth factor-beta activation in irradiated routine mammary gland. J. Clin. Invest. 93(2), 892-899 (1994).
212. Li C, Wilson PB, Levine E, Barber J, Stewart AL, Kumar S: TGF-beta1 levels in pre-treatment plasma identify breast cancer patients at risk of developing post-radiotherapy fibrosis. Int. J. Cancer 84(2), 155-159 (1999).
213. Cambien F, Ricard S, Troesch A et al.: Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Temoin de l'Infarctus du Myocarde (ECTIM) Study. Hypertension 28(5), 881-887 (1996).
214. Quarmby S, Fakhoury H, Levine E et al.: Association of transforming growth factor beta-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients. Int. J. Radiat. Biol. 79(2), 137-143 (2003).
215. Fridovich I: Superoxide radical and superoxide dismutases. Ann. Rev. Biochem. 64, 97-112 (1995).
216. Pinteaux E, Copin JC, Ledig M, Tholey G: Modulation of oxygen-radical-scavenging enzymes by oxidative stress in primary cultures of rat astroglial cells. Dev. Neurosci. 18(5-6), 397-404 (1996).
217. Warner BB, Stuart L, Gebb S, Wispe JR: Redox regulation of manganese superoxide dismutase. Am. J. Physiol. 271 (1, Pt 1), L150-L158 (1996).
218. Epperly M, Bray J, Kraeger S et al.: Prevention of late effects of irradiation lung damage by manganese superoxide dismutase gene therapy. Gene Ther. 5(2), 196-208 (1998).
219. Epperly MW, Bray JA, Krager S et al.: Intratracheal injection of adenovirus containing the human MnSOD transgene protects athymic nude mice from irradiation-induced organizing alveolitis. Int. J. Radiat. Oncol. Biol. Phys. 43(1), 169-181 (1999).
220. Borgstahl GE, Parge HE, Hickey MJ et al.: Human mitochondrial manganese superoxide dismutase polymorphic variant Ile58Thr reduces activity by destabilizing the tetrameric interface. Biochemistry 35(14), 4287-4297 (1996).
221. Shimoda-Matsubayashi S, Matsumine H, Kobayashi T, Nakagawa-Hattori Y, Shimizu Y, Mizuno Y: Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. Biochem. Biophys. Res. Commun. 226(2), 561-565 (1996).
222. Green H, Ross G, Peacock J, Owen R, Yarnold J, Houlston R: Variation in the manganese superoxide dismutase gene (SOD2) is not a major cause of radiotherapy complications in breast cancer patients. Radiother. Oncol. 63(2), 213-216 (2002).
223. Ambrose HJ: SNPs and pharmacogenomics. Pharmacogenomics 3(5), 583-586 (2002).